News | March 28, 2024
WuXi Biologics breaks ground on CRDMO Center in Singapore
The CRDMO site will add 120,000L manufacturing capacity to WuXi Biologics’ global network
The CRDMO site will add 120,000L manufacturing capacity to WuXi Biologics’ global network
The facility will manufacture tablets, capsules, and injections for the oncology segment
Decision marks the first approval in Europe for an anti-PD-1/L1 therapy in resectable NSCLC based on positive overall survival results
The report underscores significant advancements in healthcare delivery, showcasing how GenAI facilitates improved diagnostic accuracy, operational efficiency and patient engagement
WINREVAIR is a breakthrough biologic for this rare, progressive disease
Combination shows consistent benefit across prespecified post-progression outcomes
Dr Madhu will oversee Apollo's hospital business and will focus on continuing to deliver the world's best clinical outcomes
Strategic multi-year research collaboration to identify novel targets with strong disease links and to accelerate clinical development
Company reaffirms commitment to reduce the global burden of HPV-related diseases, including certain cancers
From only 80 Jan Aushadhi Kendras in 2014, there are around 11,000 units operating across the country today
Subscribe To Our Newsletter & Stay Updated
